Haemonetics Corporation
Haemonetics Corporation (HAE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hae · pe ratio · data through Mar 28, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Haemonetics Corporation (HAE) measures how much investors pay for each dollar of the company's trailing earnings. HAE's current PE ratio of 34.89x is calculated by dividing its stock price of $73.69 by its TTM earnings per share of $2.11. −9.4% discount vs 5Y avg 38.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-28
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 18 fiscal years · Front-end computedMinQ1 · 25%36.5x
MedianQ3 · 75%137.0x
Max
At 34.89x, HAE's current P/E is within its average historical range over the past 18 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Haemonetics CorporationYou HAE | $3.3B | 34.89x | +70.7% | $2.11 |
 Beam Therapeutics Inc. BEAM | $3.1B | N/A | — | -$0.81 |
 Bausch Health Companies Inc. BHC | $1.9B | 16.14x | -21.0% | $0.43 |
 Concentra Group Holdings Parent, Inc. CON | $3.2B | 14.42x | -29.4% | $1.36 |
 Catalyst Pharmaceuticals, Inc. CPRX | $3.8B | 13.32x | -34.8% | $1.75 |
 Integer Holdings Corporation ITGR | $3.1B | 26.51x | +29.7% | $2.96 |
 LeMaitre Vascular, Inc. LMAT | $2.1B | 31.80x | +55.6% | $2.55 |
Industry Average 5 peers with valid PE | — | 20.44x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-28Latest FY2026 | 26.20x | $2.06 | +38.1% | |
2025-03-29 FY2025 | 18.97x | $3.33 | -48.1% | |
2024-03-31 FY2024 | 36.57x | $2.32 | +0.4% | |
2023-03-31 FY2023 | 36.41x | $2.27 | -51.1% | |
2022-03-31 FY2022 | 74.40x | $0.85 | +5.1% | |
2021-03-31 FY2021 | 70.81x | $1.57 | +7.3% | |
2020-03-31 FY2020 | 66.02x | $1.51 | -21.5% | |
2019-03-31 FY2019 | 84.06x | $1.07 | -0.7% | |
2018-03-31 FY2018 | 84.69x | $0.86 | — | |
2017-03-31 FY2017 | — | $-0.51 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Haemonetics Corporation (HAE) measures how much investors pay for each dollar of the company's trailing earnings. HAE's current PE ratio of 34.89x is calculated by dividing its stock price of $73.69 by its TTM earnings per share of $2.11.
Frequently asked questions
HAE pe ratio · 6 questionsHAE's current PE ratio is 34.89x as of 2026-06-08, based on a stock price of $73.69 and TTM EPS of $2.11. Data sourced from Financial Modeling Prep via HAE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Haemonetics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08